SCHEMBL1574963

SCHEMBL1574963

Cc1ccc(NC(=O)N2CC(N(C)c3ccccc3)C2)cc1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.58
RAB9A P51151 6/20 0.58
MAPT P10636 4/20 0.58
TP53 P04637 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
HTT P42858 3/20 0.58
NFKB1 P19838 2/20 0.58
NFKB2 Q00653 2/20 0.58
RELA Q04206 2/20 0.58
PKM P14618 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
FAAH O00519 1/20 0.45
CYP3A4 P08684 1/20 0.45
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
FKBP5 Q13451 1/20 0.43
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574624 0.86 GRIN2B (0.56) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1575215 0.86 GRIN2B (0.52) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1574682 0.85 ALDH1A1 (0.56) RAB9AMAPTSMN1; SMN2KMT2AFAAH
SCHEMBL1574526 0.85 KDM4E (0.48) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1575245 0.85 RAB9A (0.50) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1574979 0.85 NPC1 (0.55) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1574878 0.84 NPC1 (0.61) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1574584 0.83 NPC1 (0.53) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL1574638 0.82 GRIN2B (0.57) NPC1RAB9AMAPTSMN1; SMN2HTT
SCHEMBL1574853 0.82 MAPT (0.54) NPC1RAB9AMAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-B1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO (JP) 2015-02-25 EP disclosed
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB NPC1 413/4885RAB9A 898/4885MAPT 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.